BioCentury
ARTICLE | Company News

CSPC's AlaMab gets rights to UT Health San Antonio's mAbs

July 6, 2017 6:34 PM UTC

The University of Texas' UT Health San Antonio granted the AlaMab Therapeutics Inc. subsidiary of CSPC Pharmaceutical Group Ltd. (HKSE:1093; Pink:CHPTY) exclusive, worldwide rights to IP covering two protein channel mAbs. AlaMab's license covers the mAbs' therapeutic and diagnostic use to treat breast cancer bone metastasis and spinal cord injury. Both are in preclinical testing.

The university is to receive total license fees of $4.5 million and is eligible for up to $109.5 million in additional milestones, plus royalties...